ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1323

Evaluation of Prolidase and HIF-1α Levels in Patients with Familial Mediterranean Fever (FMF)

Meliha BAYRAM1, Mehmet Emin DERİN2, Halef Okan DOĞAN3, Gökmen ASAN4, Mehtap ŞAHİN3 and Ali Şahin5, 1internal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, 2Rheumatology-internal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, 3Biochemistry, Cumhuriyet University Medical Faculty, sivas, Turkey, 4İnternal medicine, Cumhuriyet University Medical Faculty, sivas, Turkey, 5Department of Rheumatology, Cumhuriyet University Faculty of Medicine, Sivas, Turkey

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Familial Mediterranean fever

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster II: Interstitial Lung Disease, Still's Disease, FMF, Polychondritis

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Familial Mediterranean Fever(FMF) is an autoinflammatory disease characterized by recurrent fever attacks, sterile peritonitis, pleural inflammation, arthritis and / or  erysipelas like rash. Prolidase is a specific imidodipeptidase that plays a role in collagen degradation. HIF-1α is an important protein in the regulation of immunological response, hemostasis, vascularization and anaerobic (oxygen-free) metabolism. Serum prolidase activity in patients with ankylosing spondylitis(AS) was statistically significantly lower than in the control and rheumatoid arthiritis(RA) groups.Prolidase activity was not significantly different in patients with RA compared to the control group. In patients with Behçet’s disease, prolidase activity was statistically significantly higher than in healthy control group.In FMF patients, the effect of prolidase enzyme is unknown.The aim of the study is to compare serum prolidase and HIF-1 α levels in patients with FMF in attack-free period and healthy control group.Methods: Between August 2017 and December 2017, sixty patients who diagnosed FMF according to the criteria of the tel- and sixty healthy volunteers were enrolled in the study. All of FMF patients were under traetment of colchicine (1-1.5mg). Clinical findings and PRAS scores of all patients and were recorded.Blood tests were examined by Elisa method. The study protocol was approved by the local ethics committee.Results: Laboratory findings and basic characteristics of FMF and healthy control group are shown in Table1. In this study, mean serum prolidase level was measured as 72.1 (25.1-114.9) ng/ml in FMF group and 30.7 (21.3-86.2) ng/ml in healthy control (HC) group (Figure 1). There was statistically significant difference between two groups (p=0.018). The mean serum levels of HIF-1α in the FMF group were measured as 482.0(292.0-3967.0) pg/ml and 632.0(362.0-927.0) pg/ml in the HC group. There was no statistically significant difference between the two groups (p<0.05). According to ROC analysis, optimal levels of serum prolidase (>54.03 ng/ml; sensitivity was 65% and specificity was 68.3%, p<0.05). There was no significant difference between serum prolidase and HIF-1α levels in the mild, moderate and severe patient groups according to PRAS score (p>0.05). There was no significant correlation between laboratory findings, sex, age, and prolidase (p>0.05, r<0.25).Conclusion: Serum prolidase enzyme levels in FMF patients with attack-free period were significantly higher than in the healthy control group. There was no significant difference between the two groups at HIF-1α level. High prolidase enzyme levels may be associated with clinical or subclinical inflammation in FMF patients. However, the role of prolidase and HIF1-α in the FMF disease needs to be clarified with more extensive and comprehensive studies.

Variable

Group

p

FMF (n=60)

Healthy control (n=60)

Age

33.45±11.91

26.58±8.67

<0.001

Sex

 

 

 

   Female

33(55.0)

30(50.0)

0.583

   Male

27(45.0)

30(50.0)

 

Neutrophil (%)

62.27±10.06

60.31±7.97

0.238

Lymphocyte (%)

29.26±9.03

31.49±6.71

0.127

N/L

2.2(1.5-2.9)

1.9(1.5-2.4)

0.091

Platelet (ul)

260.47±71.30

273.82±70.36

0.304

Hemoglobin (g/dl)

13,87±1.80

14.92±1.65

0.001

Leukocyte(WBC) (fl)

3.8(3.8-3.9)

3.9(3.8-3.9)

0.431

Creatinine (mg/dl)

0.7(0.6-0.9)

0.8(0.7-0.9)

0.121

ALT(U/L)

17.5(12.0-26.8)

15.5(11.3-21.5)

0.193

AST(U/L)

18.0(15.3-20.0)

16.0(14.0-19.0)

0.060

MPV (fl)

9.5(8.9-10.4)

9.6(8.8-10.5)

0.795

CRP (mg/l)

3.9(2.2-8.9)

3.0(1.9-4.0)

0.011

Fibrinogen (mg/dl)

326.0(266.3-412.3)

284.0(265.0-336.3)

0.227

Erythrocyte sedimentation rate (mm/h)

10,0(5,0-26,5)

7,5(4,0-10,0)

0,003

The data are expressed as mean ± standard deviation, median (1th quarter-3th quarter) and n(%).

 


Disclosure: M. BAYRAM, None; M. E. DERİN, None; H. O. DOĞAN, None; G. ASAN, None; M. ŞAHİN, None; A. Şahin, None.

To cite this abstract in AMA style:

BAYRAM M, DERİN ME, DOĞAN HO, ASAN G, ŞAHİN M, Şahin A. Evaluation of Prolidase and HIF-1α Levels in Patients with Familial Mediterranean Fever (FMF) [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-prolidase-and-hif-1%ce%b1-levels-in-patients-with-familial-mediterranean-fever-fmf/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-prolidase-and-hif-1%ce%b1-levels-in-patients-with-familial-mediterranean-fever-fmf/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology